丰山集团(603810) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 441,406,976.76, representing a decrease of 2.84% compared to the same period last year[5] - The net profit attributable to shareholders was CNY 30,534,902.58, down 39.39% year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 26,563,165.16, a decline of 44.93% compared to the previous year[5] - The basic earnings per share were CNY 0.19, down 38.71% from the same period last year[5] - The weighted average return on equity was 2.13%, a decrease of 1.56 percentage points year-on-year[5] - Total operating revenue for Q1 2022 was CNY 441,406,976.76, a decrease of 2% compared to CNY 454,318,728.70 in Q1 2021[22] - Net profit for Q1 2022 was CNY 30,534,902.58, down 39.4% from CNY 50,375,579.42 in Q1 2021[23] - Earnings per share for Q1 2022 were CNY 0.19, compared to CNY 0.31 in Q1 2021[24] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -117,559,973.13, a significant decrease of 147.55% year-on-year[5] - The company's cash and cash equivalents decreased to RMB 281,869,129.23 from RMB 364,706,984.85[18] - Cash flow from operating activities showed a net outflow of CNY 117,559,973.13, worsening from a net outflow of CNY 47,489,648.54 in Q1 2021[27] - Cash inflow from investment activities was CNY 198,248,341.42, slightly up from CNY 197,262,676.09 in the previous year[27] - The net cash flow from investment activities was $22,309,734.30, a significant improvement compared to the previous year's negative cash flow of -$193,427,492.25[28] - The ending balance of cash and cash equivalents was $214,427,299.75, down from $323,104,204.94 in the prior year[28] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,088,600,663.62, an increase of 4.81% from the end of the previous year[6] - The total current liabilities increased to RMB 592,119,247.84 from RMB 529,662,101.28[19] - Total liabilities increased to CNY 636,947,805.29, compared to CNY 571,996,007.73 in the previous year, reflecting a growth of 11.3%[20] - The total equity attributable to shareholders rose to CNY 1,451,652,858.33, up from CNY 1,420,679,028.35, marking a 2.2% increase[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 14,351[12] - The largest shareholder, Yin Fengshan, holds 67,725,478 shares, representing 41.7% of the total shares[12] Operational Changes - The company reported a significant increase in accounts receivable by 98.59%, primarily due to sales with outstanding payment terms[8] - Financial expenses surged by 105.82%, mainly attributed to fluctuations in the USD exchange rate[8] - The company plans to upgrade its production line to increase capacity to 1,700 tons of active ingredients and 1,083 tons of by-products[14] - The company has made strategic adjustments to its fundraising projects, focusing on optimizing production processes and capacity[14] Inventory and Expenses - The company's inventory increased to RMB 393,959,301.20 from RMB 343,560,393.05, indicating a rise in stock levels[18] - Total operating costs increased to CNY 404,894,862.17, up 3.2% from CNY 391,714,150.25 in the same period last year[22] - Research and development expenses for Q1 2022 were CNY 12,316,781.49, an increase of 21.6% from CNY 10,130,613.97 in Q1 2021[23] - The company reported a decrease in sales expenses to CNY 12,249,632.55 from CNY 9,481,025.26 in the previous year, indicating a 29.5% increase[23] Accounting Practices - The company did not apply the new accounting standards starting from 2022, indicating a continuation of previous accounting practices[28]